Menopause
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.
Latest News
Soy didn’t up all-cause mortality in breast cancer survivors
The ongoing study tracks with previous work showing no risk from dietary soy.
From the Journals
Most oral HRT linked to increased VTE risk
From the Journals
Healthier lifestyle in midlife women reduces subclinical carotid atherosclerosis
Menopausal women who choose a healthier lifestyle – particularly not smoking – have less subclinical carotid atherosclerosis.
Conference Coverage
Estetrol safely limited menopause symptoms in a phase 2b study
E4 has “a remarkably safe profile,” which Dr. Wulf H. Utian describes as “the first natural oral estrogen with the safety profile of a transdermal...
Conference Coverage
No signal for CV, breast effects with bioidentical vaginal estrogen for dyspareunia
Low-dose vaginal softgel is approved for treating moderate to severe dyspareunia associated with menopause.
Conference Coverage
For dyspareunia, intravaginal prasterone may work best soon after menopause
Age and previous hormone replacement therapy did not influence prasterone’s efficacy in treating dyspareunia.
From the Journals
No falls, fractures, or bone density benefits from vitamin D supplements
Vitamin D supplementation does not appear to reduce the risk of falls or fracture or to improve bone mineral density.
Conference Coverage
Zoledronate reduces fracture risk in elderly women with osteopenia
Women with osteopenia who received intravenous zoledronate had a significantly lower risk of fractures.
Conference Coverage
Migraine and menopause: Longitudinal study shows what to expect
From the Journals
High testosterone in postmenopausal women may add CVD risk
Having more testosterone than estrogen may spell heart disease after menopause.